SpyBiotech is a clinical-stage biotechnology company focused on developing innovative vaccines using its proprietary protein superglue technology, known as SpyTag/SpyCatcher. This unique platform allows for the rapid and efficient creation of safe and effective vaccines targeting infectious diseases and cancer. The company aims to address significant health challenges, particularly in areas where existing vaccines are lacking. Their lead candidate is a vaccine for Cytomegalovirus (CMV), a widespread virus that poses serious health risks, especially to infants and immunocompromised individuals. The technology enables the development of virus-like particles (VLPs) that can effectively stimulate the immune system, thereby enhancing the potential for successful vaccination.

Currently, SpyBiotech is conducting a Phase I clinical trial in the UK to evaluate the safety and immunogenicity of its CMV vaccine candidate. The trial aims to determine the optimal dosage and formulation for further development, addressing a critical unmet medical need in vaccine development. CMV is recognized as a high-priority target for vaccine development due to its prevalence and the severe complications it can cause, particularly in vulnerable populations. By leveraging its advanced protein superglue technology, SpyBiotech is positioned to make significant advancements in vaccine efficacy and accessibility, ultimately contributing to improved public health outcomes.

United Kingdom

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. 

SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. 

The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year. 

SpyBiotech

Company Details